# Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

> **NCT03237377** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 9 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **RADIATION:** Thoracic Radiation
- **PROCEDURE:** lobectomy
- **DRUG:** Standard of care adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT03237377
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-12
- **Primary completion:** 2021-11-04
- **Final completion:** 2024-05-23
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03237377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03237377, "Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03237377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*